In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
Shares of Innate Pharma were up 4.5% at 2.45 euros mid-afternoon, after it announced that French pharma major and Sanofi has progressed their collaboration. 19 December 2023
Pharmaceutical
Hoping to capitalize on a tsunami of interest in GLP-1 agonists for weight loss, Structure Therapeutics has now published Phase IIa data for its oral candidate, but investors are not happy. 19 December 2023
Biosimilars
Amid the ever-declining drug imports from Western countries, Russia is ready to increase supplies of drugs from so-called “friendly” countries, The Pharma Letter’s local correspondent report. 19 December 2023
Biotechnology
Shares in US biotech Checkpoint Therapeutics slumped by nearly half on Monday. 19 December 2023
Pharmaceutical
In a new move within the pharmaceutical industry, French pharma major Sanofi has entered into a $140 million deal with Aqemia, a French pharmaceutical technology company. 19 December 2023
Biotechnology
UK pharma major GSK (LSE: GSK) has released positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial investigating Jemperli (dostarlimab). 19 December 2023
Biotechnology
The European Commission has extended the approval of Evkeeza (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged five to 11 years with homozygous familial hypercholesterolemia (HoFH). 19 December 2023
Biotechnology
US biotech bluebird bio saw a negative reaction to its proposed sales of shares, with the stock closing down 6.7% and a further15.6% to $2.575 in after-hours trading on Monday. 19 December 2023
Pharmaceutical
Rain Oncology is to be acquired by Pathos AI for $1.16 per share, a 17% premium on the former firm’s share price. 18 December 2023
Pharmaceutical
Vicore Pharma, a Swedish pharma company seeking to unlock the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has announced that Bertil Lindmark will join as chief medical officer. 18 December 2023
Biotechnology
US women’s health specialist Organon today announced an agreement with pharma major Eli Lilly to become the sole distributor and promoter for two of the latter’s migraine medicines, 18 December 2023
Pharmaceutical
Lif, the industry organization for Danish and foreign pharmaceutical companies in Denmark, has held a debate to discuss access to new medicines. 18 December 2023
Biotechnology
New Jersey, USA-based cancer company Bristol Myers Squibb has announced that the Phase III RELATIVITY-123 trial will be stopped, based on a futility analysis. 18 December 2023
Biotechnology
Shares of Blue Water Biotech were down 11.8% at $0.24 pre-market, after it announced the acquisition of Proteomedix. 18 December 2023
Biotechnology
The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab). 18 December 2023
Pharmaceutical
Swiss specialty pharma Santhera Pharmaceuticals has announced that Agamree (vamorolone) has been approved in the European Union (EU) to treat Duchenne muscular dystrophy (DMD) in patients four years of age and older, independent of the underlying mutation and ambulatory status. 18 December 2023
Biotechnology
As geopolitical tension intensifies between China and the US-led West, more Chinese biotechs are actively seeking growth opportunities in the vast emerging markets, or the markets outside the USA and European Union, especially the geographically nascent ASEAN region and the wealthy Middle East region. 18 December 2023
Biotechnology
Australian biotech Neuren Pharmaceuticals saw its share jump more than 22% to A$29.5 today, after it announced top-line results from its Phase II clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). 18 December 2023
Biotechnology
French immuno-oncology company Innate Pharma has announced the resignation of chief executive Mondher Mahjoubi. 18 December 2023
Biotechnology
The US Food and Drug Administration (FDA) on Friday approved Padcev (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with Keytruda (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally-advanced or metastatic urothelial cancer (la/mUC). 18 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze